Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients

Keyphrases

• Lithium 100%
• Lithium Augmentation 100%
• Schizophrenic Patients 100%
• Placebo 50%
• Schizophrenia 33%
• No Significant Difference 33%
• Fluphenazine Decanoate 33%
• Placebo Groups 33%
• Antipsychotics 16%
• Placebo-controlled Trial 16%
• Treatment Strategy 16%
• Psychosis 16%
• Schizophrenia Symptoms 16%
• Augmentation Therapy 16%
• DSM-III 16%
• Intent-to-treat Analysis 16%
• Demographic Variables 16%
• Brief Psychiatric Rating Scale 16%
• Schizoaffective Disorder 16%
• Common Strategies 16%

Neuroscience

• Placebo 100%
• Fluphenazine 33%
• Decanoic Acid 33%
• Antipsychotic 33%
• Schizoaffective Disorder 16%
• Typical Antipsychotic 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Antipsychotic 33%
• Fluphenazine Decanoate 33%
• DSM-III 16%
• Schizoaffective Psychosis 16%
• Typical Antipsychotic 16%